PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Volume: 372, Issue: 4, Pages: 311 - 319
Published: Jan 21, 2015
Abstract
BACKGROUND Preclinical studies suggest that Reed–Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin’s lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signaling. We hypothesized that nivolumab, a PD-1–blocking antibody, could...
Paper Details
Title
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Published Date
Jan 21, 2015
Volume
372
Issue
4
Pages
311 - 319
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.